Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
about
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewHair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeedingMetabolism and disposition of bupropion in pregnant baboons (Papio cynocephalus).Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyA randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancyObstetric Pharmacokinetic Dosing Studies are Urgently Needed.Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.A targeted proteomics approach for profiling murine cytochrome P450 expression.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013.Basic obstetric pharmacology.Antiretroviral Pharmacokinetics in Pregnant Women.Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?Pregnancy-related pharmacokinetic changes.Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Effect of pregnancy on the pharmacokinetic interaction between efavirenz and lumefantrine in HIV-malaria co-infection
P2860
Q28109657-686ACF60-0585-4AB9-9743-1A97C52BC389Q30679524-D767F30F-F566-47FD-9030-2DF677839E9DQ34186008-C3271D30-D29B-4978-993E-945EF83C5A68Q34323195-04B865AF-EC7A-4014-8016-67C5FD777266Q34429204-2CD97128-DB19-4DDE-ADC7-BFDCCB688D19Q35102702-8AD03784-193A-4A62-811C-2EE44C02A168Q35211432-5E46A7AF-A509-4FC9-90E4-1306B2ABECDBQ37026878-583BE3D8-F8E8-451F-9CD2-051108DD0D8FQ37286950-48EB0420-1D17-40A1-9A57-DF60063CE13DQ37575742-35739CE2-F660-4217-AF31-667908D065A0Q37600844-5E399ECE-687E-4B39-812C-78D876DF52D7Q37707721-3BBEBD4D-5157-46D2-A1E0-BE7C9FD3C7AEQ38047214-F6CB6864-6E19-4FFC-8DAA-8FF13ACCAA98Q38051400-536F68A9-EF57-4E5F-AA2D-02F54D54396FQ38206255-B278A441-D898-4D79-9927-88557236DB54Q38256590-7C2B15C6-2DAE-4500-A9A4-2374E9A27633Q38571596-E6680CD9-7338-4719-BCC9-760C17C5298FQ38630880-5E9168DA-2893-4F7C-A82B-D7E1B94AEBC2Q38809225-BE3A6703-4172-423A-B609-D2C62D037A5EQ38828635-91CB5473-E5B2-409C-9677-FFC14833B3D4Q38872808-B55A03FE-4C82-4225-8C17-B8708FD2FA64Q46158508-1F4D4033-0EAC-4707-BAEE-A736F675F7C5Q47553402-BD4446C9-E104-475D-BACA-B33DA148F71DQ47906608-56268E74-9173-465D-A834-8B638D35F3EFQ56346858-CE37DC44-D26E-4295-B9E0-358329BB4BCF
P2860
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
@ast
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
@en
type
label
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
@ast
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
@en
prefLabel
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
@ast
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
@en
P2093
P2860
P1476
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
@en
P2093
Alice Stek
Brookie M Best
Chanon Neungton
Chureeratana Bowonwatanuwong
Edmund Capparelli
IMPAACT P1026s Team
Mark Mirochnick
Pannee Sirivatanapa
Prapap Yuthavisuthi
Sinart Prommas
P2860
P304
P356
10.1097/QAI.0B013E31823FF052
P407
P577
2012-03-01T00:00:00Z